Nurix Therapeutics (NASDAQ: NRIX) announced the achievement of a $7 million research milestone under its strategic collaboration with Pfizer. This payment targets the discovery and development of degrader antibody conjugates (DACs), an emerging therapeutic modality.

The milestone brings the total amount received by Nurix under this agreement to $82 million. The collaboration, originally entered into with Seagen Inc. (now part of Pfizer) in September 2023, includes an upfront payment of $60 million and potential future milestones totaling up to $3.4 billion.

Collaboration financial structure

The deal provides Nurix with significant non-dilutive funding through upfronts and milestones, alongside long-term royalty streams. The table below outlines the key financial components disclosed:

Strategic significance of DACs

Degrader antibody conjugates combine the cell selectivity of antibodies with the catalytic mechanism of targeted protein degraders. Unlike traditional antibody-drug conjugates (ADCs) that deliver cytotoxic payloads, DACs deliver targeted protein degraders to eliminate specific disease-driving proteins. This approach offers multiple layers of selectivity based on cell-surface antigen expression and E3 ligase activity.

Pipeline context

Nurix focuses on targeted protein degradation medicines for cancer and autoimmune diseases. Its clinical-stage oncology pipeline includes bexobrutideg, co-developed with Roche, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). The company also maintains collaborations with Gilead Sciences and Sanofi for other clinical-stage candidates.

What the numbers show

The $7 million milestone represents approximately 11.6% of the total $82 million received to date, indicating that the majority of cash inflows remain tied to the initial upfront rather than ongoing research achievements. With potential milestones capped at $3.4 billion, the current received amount constitutes roughly 2.4% of the maximum theoretical value, highlighting the early stage of value realization in this partnership.

Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced the appointment of Wes Burwell as its chief human resources officer on August 20, 2026. Burwell will serve as a member of the company’s executive management team, leading the human resources organization as Nurix advances its late-stage clinical pipeline and prepares for commercialization.

The hiring coincides with a strategic shift for the Brisbane, California-based biopharmaceutical company. Arthur T. Sands, M.D., Ph.D., president and chief executive officer, stated that Nurix is evolving from a research and early clinical-stage company into a fully integrated biopharmaceutical organization. Building the capabilities, leadership, and culture required for this transformation is cited as vital to advancing the pipeline.

Burwell brings more than 20 years of human resources leadership experience in life science organizations. Prior to joining Nurix, he served as vice president of human resources at Bolt Biotherapeutics. Earlier in his career, he held senior roles at Global Blood Therapeutics, where he guided the company’s growth from early clinical development through the commercialization of its first therapy.

Pipeline Context

Nurix is developing targeted protein degradation medicines for cancer and inflammatory diseases. Its clinical-stage oncology pipeline includes bexobrutideg, a BTK degrader co-developed with Roche, and NX-1607, an inhibitor of CBL-B. The autoimmune disease pipeline features bexobrutideg in collaboration with Roche, along with degraders of IRAK4 with Gilead and STAT6 with Sanofi.

Burwell stated that the company’s scientific leadership and differentiated pipeline create an opportunity to build an organization capable of delivering innovative medicines globally. He holds an M.B.A. in International Business from the University of San Francisco and a bachelor’s degree in human resource management from Golden Gate University.